Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Bhupendra O. Khatri"'
Autor:
Bhupendra O. Khatri
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 9 (2016)
Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in the USA as an oral therapy for relapsing forms of multiple sclerosis, long-term clinical experience with this therapy has been increasing. This revie
Externí odkaz:
https://doaj.org/article/0b23eb4620544242ab224372de325b0b
Autor:
Elizabeth M. Poole, Patricia K. Coyle, Steve Cavalier, Bhupendra O. Khatri, Keith R. Edwards, Ralf Gold, Miqun Robinson, Myriam Benamor, José Meca-Lallana, Pascal Rufi
Publikováno v:
Multiple Sclerosis and Related Disorders. 31:157-164
The demographics and management of patients with multiple sclerosis (MS) differ across geographical regions, but it is unclear whether/how these differences affect treatment outcomes. The aim of this post-hoc analysis was to assess teriflunomide use
Autor:
Bhupendra O. Khatri, Matt Mandel, Kiren Kresa-Reahl, Chakkarin Burudpakdee, Keith R. Edwards, Jeffrey Chavin, Robert Zivadinov, Bianca Weinstock-Guttman, Karthinathan Thangavelu, Stanley Cohan, Michael G. Dwyer, Niels Bergsland
Publikováno v:
Journal of Comparative Effectiveness Research. 8:305-316
Aim: Head-to-head clinical trials of teriflunomide (TFM) versus dimethyl fumarate (DMF) have not been conducted. Objectives: To compare the real-world effectiveness of TFM versus DMF. Methods: Anonymized data were collected from patients with relapsi
Autor:
Claudia Prada, Mariko Kita, Pavle Repovic, Daniel S. Bandari, Emily Riser, Bhupendra O. Khatri, Sherrill Loring, Jeffrey Greenstein, Nick Everage, Guy J. Buckle, Katherine Riester, Mark Gudesblatt, Irene Koulinska, Bianca Weinstock-Guttman, Ben Thrower, Monica Mann
Publikováno v:
Multiple Sclerosis Journal-Experimental, Translational and Clinical
Background In patients treated with dimethyl fumarate, absolute lymphocyte count decline typically occurs during the first year and then plateaus; early drops have been associated with the development of severe prolonged lymphopenia. Objective We inv
Publikováno v:
Multiple sclerosis and related disorders. 18
Background Dimethyl fumarate (DMF) reduces absolute lymphocyte counts, CD4, and CD8 counts, without significantly affecting total white blood cell counts. However, the recovery rate of these cells after discontinuation of DMF is unknown. The effect o
Autor:
Tayo Olapo, Mary Dukic, Lisa Sershon, Bhupendra O. Khatri, Jeffery S. Garland, Joseph R. Berger, Eileen Rehn, Jean Sesing, John Kramer
Publikováno v:
Multiple Sclerosis and Related Disorders. 4:377-379
Dimethyl fumarate (Tecfidera™) is an effective therapy for relapsing forms of multiple sclerosis (MS). Our study suggests that this drug may have immunosuppressive properties evidenced by significant sustained reduction in CD8 lymphocyte counts and
Autor:
John Kramer, Bhupendra O. Khatri
Publikováno v:
Clinical Investigation. 1:575-578
Fingolimod (Gilenya®) is the first oral immunomodulating drug approved for relapsing–remitting multiple sclerosis. Its novel mechanism of action inhibits the egress of autoreactive B and T cells from lymph nodes, thus preventing them from crossing
Publikováno v:
CONTINUUM: Lifelong Learning in Neurology. 16:58-77
For a disease whose cause remains elusive, there has been a paradoxical growth in multiple sclerosis (MS) therapeutics. During the past 17 years, six therapeutic drugs for MS were brought to market. All of these disease-modifying therapies (DMTs) hav
Publikováno v:
International Journal of MS Care. 12:34-41
Health-related quality of life (HRQOL) is an important consideration for patients with a chronic disease such as multiple sclerosis (MS). We conducted a review of published articles and conference proceedings to evaluate the use of patient-reported m
Autor:
Sandrine Brette, Steve Cavalier, Bhupendra O. Khatri, Ralf Gold, Keith R. Edwards, Patricia K. Coyle, Pascal Rufi, Prashant Kulkarni
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 88:A53.2-A53
Introduction The phase 4 Teri-PRO study (NCT01895335) investigated patient-reported outcomes (PROs), effectiveness, safety, and tolerability of teriflunomide in a real-world setting, and included a large proportion of patients with RMS who had receiv